Wi de yuz kuki dɛn fɔ mek yu ɛkspiriɛns bɛtɛ. We yu kɔntinyu fɔ yuz dis sayt, yu go gri fɔ mek wi yuz kuki dɛn. Mɔ infɔmeshɔn.
We yu klik “Allow All”, yu gri fɔ mek dɛn kip kuki dɛn na yu divays fɔ mek yu ebul fɔ go na di sayt fayn fayn wan, fɔ analayz di we aw yu de yuz di sayt, ɛn fɔ sɔpɔt wi fɔ gi fri, opin-akses sayɛns kɔntinyu. Mɔ infɔmeshɔn.
Yu tink se wan simpul urine test go ebul fɔ no di fɔs stej Alzaima sik, we go mek di rod fɔ mek dɛn du mas skrinin program? Di nyu Frontiers in Aging Neuroscience stɔdi rili sho dis. Di risach pipul dɛm bin tɛst wan big grup pan Alzaima pasɛnt dɛm wae gɛt difrɛn kayn sik ɛn wae gɛt wɛl bɔdi wae nɔrmal fɔ no bɔt difrɛns pan urine biomarkers.
Dɛn fain se fɔmik asid na di urine na sɛnsitiv mak fɔ sɔbjɛktiv kɔgnitiv dɛklin ɛn i kin herald di fɔs stej dɛm fɔ Alzaima sik. Di we dɛn we de naw fɔ no if pɔsin gɛt Alzaima sik, dɛn dia, dɛn nɔ kin izi fɔ dɛn, ɛn dɛn nɔ kin gri fɔ mek dɛn chɛk dɛn ɔltɛm. Dis min se dɛn kin jɔs no bɔku pan di sik pipul dɛn we i dɔn tu let fɔ gɛt di tritmɛnt we go wok fayn. Bɔt, wan nɔ-invasive, i nɔ dia, ɛn izi fɔ urinalysis fɔ fɔmik asid kin bi jɔs wetin dɔktɔ dɛn de aks fɔ fɔ mek dɛn chɛk am kwik kwik wan.
Di wan dɛn we rayt dis buk tɔk se: “Alzaima sik na sik we nɔ de dɔn ɛn we nɔ kin izi fɔ du, we min se i kin kam ɛn kɔntinyu fɔ de fɔ bɔku ia bifo i kam fɔ no se pɔsin nɔ ebul fɔ ɔndastand sɔntin.” "Di fɔs stej dɛm fɔ di sik kin apin bifo di stej wae de mɛk pɔrsin gɛt dis maynia sik wae nɔr kin chenj, wae na golden winda fɔ intavɛnshɔn ɛn tritmɛnt. So, i fayn fɔ mek dɛn du big big skrinin fɔ di fɔs stej Alzaima sik pan ol pipul dɛm."
So, if fɔ ɛp kwik kwik wan impɔtant, wetin mek wi nɔ gɛt rutin skrinin program fɔ di fɔs stej Alzaima sik? Di prɔblɛm de pan di we aw dɔktɔ dɛn de yuz fɔ no di sik naw. Dɛn tin ya na positron emission tomography of di bren, we dia ɛn we de mek di sikman dɛn gɛt raytin. Bayomakɛr tɛst dɛn de bak we kin no Alzaima, bɔt dɛn kin nid fɔ pul invayv blɔd ɔ fɔ pank di lɔmba fɔ gɛt wata we de na di sɛribrospaynal, we di sik pipul dɛn kin de put ɔf.
Bɔt di tɛst fɔ urine nɔ de invasive ɛn i izi fɔ du, we mek dɛn fayn fɔ mek dɛn du mas skrinin. Pan ɔl we di wan dɛn we de stɔdi bɔt dis dɔn no di urine biomarkers fɔ Alzheimer’s disease, nɔbɔdi nɔ fayn fɔ no di fɔs stej fɔ di sik, we min se di golden winda fɔ trit di sik kwik kwik wan stil de.
Di risach pipul dɛm we de biɛn di nyu stɔdi dɔn stɔdi wan ɔrganik kɔmpawnd we dɛn kɔl fɔmaldehayd as urine biomarker fɔ Alzaima sik. Bɔt, rum de fɔ mek dɛn ebul fɔ no di sik kwik kwik wan. insay dis las stכdi, dεn fכkus pan fכmat, we na fכmaldehayd mεtabolayt, fכ si if i de wok bεtεh as bayomak.
A tot ɔl 574 pipul dɛn tek pat pan di stɔdi, ɛn di patisipan dɛn na bin ɔl tu kɔgnitiv nɔmal wɛlbɔdi volontia ɔ dɛn bin gɛt difrɛn digri fɔ di sik prɔgrɛs, frɔm sɔbjɛktiv kɔgnitiv dɛklin to kɔmplit sik. Di wan dɛn we du di risach bin analayz di urine ɛn blɔd sɛmpul dɛn frɔm di wan dɛn we tek pat ɛn du wan saykolojik asɛsmɛnt.
Di stכdi fכnshכn se di urinary fכmik asid lεvεl dεm bin sכmtεm εlevεt in כl di Alzaima sik grup dεm εn kכrεlat wit kכgnitiv dεklin kכmpεr to hεlty kכntrol dεm, inklud di εli sכbjεktiv kכgnitiv dεklin grup. dis sho se fכmik asid kin bi sεnsitiv bayomak fכ di fכs stej dεm fכ di Alzaima sik.
I fayn fɔ no se we di wan dɛn we du di risach bin analayz di urine formatte levels in kɔmbayn wit Alzheimer’s blood biomarkers, dɛn bin si se dɛn kin ebul fɔ tɔk mɔ kɔrɛkt wan di stej fɔ di sik we pɔsin de go tru. Bɔt dɛn nid fɔ du mɔ risach fɔ ɔndastand di link bitwin Alzaima ɛn fɔmik asid.
Di wan dɛn we rayt dis buk tɔk se: “Urin fɔmik asid dɔn sho se i gɛt fayn fayn sɛnsitiviti fɔ chɛk fɔ Alzaima sik kwik kwik wan.” “Urine biomarker testing for Alzheimer’s disease na tin we izi fɔ du ɛn i nɔ de tek bɔku mɔni ɛn dɛn fɔ put am insay di rutin wɛlbɔdi skrinin fɔ ol pipul dɛn.”
Wang, Y. ɛn ɔda pipul dɛn. (2022) Sistεmatik rivyu כf urinary fכmik asid as pכtεnshal nyu bayomak fכ Alzaima sik. Frontiers in di nyurobayoloji fɔ ol pipul dɛn. doi.org/10.3389/fnagi.2022.1046066, ɛn di ɔda wan dɛn.
Tags: ol, Alzaima sik, bayomak, blɔd, bren, krɛse, krɛse sik, kɔmpawnd, dimɛns, diagnostik, dɔktɔ, fɔmaldehayd, nyurolɔji, positron emission tomography, risach, tomography, urinalysis
Na Pittcon 2023 na Filadɛlfia, Pɛnsilvenia, wi bin intavyu Prɔfɛsɔ Josɛf Wang, we win dis ia Ralph N. Adams Prayz insay Analitikal Kɛmistri, bɔt di versatility of biosensor technology.
Insay dis intavyu, wi tɔk bɔt di respiratory biopsy ɛn aw i kin bi yusful tul fɔ stɔdi bayomak fɔ no di sik kwik kwik wan wit Mariana Leal, Tim Lida na Owlstone Medical.
As pat pan wi SLAS US 2023 rivyu, wi de tɔk bɔt di lab fɔ di fyuchu ɛn aw i go tan lɛk wit Luigi Da Via, GSK Tɛst Divɛlɔpmɛnt Tim Lid.
News-Medical.Net de gi dis mɛdikal infɔmeshɔn savis we dɛn de fala dɛn lɔ ɛn kɔndishɔn dɛn ya. Duya mɛmba se di mɛdikal infɔmeshɔn we de na dis wɛbsayt na fɔ sɔpɔt, ɛn nɔto fɔ tek in ples, di pɔsin in dɔktɔ/dɔktɔ rilayshɔn ɛn di mɛdikal advays we dɛn kin gi.